GlassScriptPhysician profile
Tonia D Kroll
NPI 1225238991
$4,122.81
in general payments reported to CMS, 2019-2025
22 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $472 · 2022: $432 · 2023: $391 · 2024: $2,616 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,664 · Travel and Lodging: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,664.03 |
| Travel and Lodging | $1,554.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $2,039.13 | 2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $618.02 | 2021-2025 | Mavenclad, Mavenclad |
| Novartis Pharmaceuticals Corporation | $550.45 | 2021-2025 | |
| Lundbeck LLC | $134.66 | 2022-2025 | Vyepti |
| Genzyme Corporation | $120.00 | 2023 | |
| Biogen, INC. | $81.06 | 2021-2024 | Tysabri, Vumerity |
| Abbvie INC. | $77.87 | 2021-2023 | |
| Pfizer INC. | $73.20 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $44.24 | 2021-2024 | Ingrezza |
| Tg Therapeutics, INC. | $43.69 | 2024-2025 | |
| Celgene Corporation | $43.06 | 2021-2024 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $41.12 | 2022-2023 | Evusheld |
| Acorda Therapeutics, INC | $40.32 | 2021-2022 | |
| Argenx US, INC. | $38.44 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $36.01 | 2024 | Nuplazid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.49 | 2021-2024 | Kisunla |
| Allergan, INC. | $30.34 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.82 | 2021 | |
| Novo Nordisk INC | $16.93 | 2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $15.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.01 | 2022 | |
| Genentech USA, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonia Kroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.